Bortenat 2 (Bortezomib) 2 mg

Indicated for the treatment of adult patients with:

• Multiple Myeloma: Both for previously untreated patients (in combination with other drugs) and for relapsed/refractory myeloma.
• Mantle Cell Lymphoma: For patients who have received at least one prior therapy.

⚠️ For medical professional administration only. NEVER administer intrathecally.

Routes of Administration:

• 💉 Subcutaneous (SC): Recommended injection into the thigh or abdomen. Associated with lower rates of peripheral neuropathy.
• 💉 Intravenous (IV): Administered as a 3-5 second bolus injection.

Typical Cycle: Twice weekly for two weeks (Days 1, 4, 8, 11) followed by a 10-day rest period (21-day cycle).

Reconstitution: Must be reconstituted with 0.9% Sodium Chloride. Concentration differs for SC vs IV use.

• Hypersensitivity to bortezomib, boron, or mannitol.
• Acute diffuse infiltrative pulmonary and pericardial disease.
• Pregnancy and breastfeeding.

Precaution: Use with caution in patients with hepatic impairment (liver problems) or severe renal impairment.